Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to -$24.4 million.

  • Fate Therapeutics' Cash from Operations rose 1714.88% to -$24.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.6 million, marking a year-over-year increase of 1605.24%. This contributed to the annual value of -$122.9 million for FY2024, which is 709.87% up from last year.
  • As of Q3 2025, Fate Therapeutics' Cash from Operations stood at -$24.4 million, which was up 1714.88% from -$24.6 million recorded in Q2 2025.
  • Over the past 5 years, Fate Therapeutics' Cash from Operations peaked at -$24.4 million during Q3 2025, and registered a low of -$75.4 million during Q4 2022.
  • Its 5-year average for Cash from Operations is -$39.4 million, with a median of -$33.4 million in 2024.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 24017.13% in 2021, then skyrocketed by 5533.41% in 2023.
  • Fate Therapeutics' Cash from Operations (Quarter) stood at -$70.3 million in 2021, then dropped by 7.25% to -$75.4 million in 2022, then surged by 51.4% to -$36.6 million in 2023, then grew by 24.12% to -$27.8 million in 2024, then rose by 12.32% to -$24.4 million in 2025.
  • Its Cash from Operations was -$24.4 million in Q3 2025, compared to -$24.6 million in Q2 2025 and -$33.8 million in Q1 2025.